ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
11 hedge funds and large institutions have $5.24M invested in ESSA Pharma in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.19% less ownership
Funds ownership: 1.88% → 1.7% (-0.19%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
84% less capital invested
Capital invested by funds: $33.1M → $5.24M (-$27.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$8.85K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$555 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.15M |
| 2 |
AIC
AWM Investment Company
New York
|
-$419K |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$267K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
EPIX Hedge Fund Activity: Q2 2017 in Review
11 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2017, worth a combined $5.24M — down 84% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EPIX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.8K. The largest seller was Deerfield Management, cutting an estimated $1.15M.
- 11 institutional investors held ESSA Pharma (EPIX) as of Q2 2017, up from 10 in Q1 2017.
- Funds reported $5.24M of ESSA Pharma stock for Q2 2017, down 84% quarter-over-quarter.
- 2 funds opened new ESSA Pharma positions in Q2 2017 and 1 closed out, a net change of +1 holder.
- The largest ESSA Pharma buyer in Q2 2017 was Citadel Advisors, an estimated $30.8K added.
- The largest ESSA Pharma seller in Q2 2017 was Deerfield Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q2 2017.